Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12692605 | 0.95 | FOLH1 (0.38) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL277717 | 0.93 | SIRT2 (0.35) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL13311697 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL14864110 | 0.91 | FOLH1 (0.38) | SIRT2SIRT1HDAC4FOLH1TPSAB1 | |
| SCHEMBL14753619 | 0.90 | FOLH1 (0.36) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL12419151 | 0.90 | SIRT2 (0.38) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL13311706 | 0.89 | SIRT2 (0.34) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL14864111 | 0.89 | FOLH1 (0.37) | SIRT2HDAC4FOLH1TPSAB1 | |
| SCHEMBL9910894 | 0.89 | SIRT2 (0.40) | SIRT2SIRT1HDAC4MEF2DEP300 | |
| SCHEMBL12038058 | 0.89 | FOLH1 (0.35) | SIRT2SIRT1HDAC4MEF2DEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732189-B2 | Methods for preparing polymeric reagents and compositions of polymeric reagents | NEKTAR THERAPEUTICS (US) | 2017-08-15 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-20160289382-A1 | METHODS FOR PREPARING POLYMERIC REAGENTS AND COMPOSITIONS OF POLYMERIC REAGENTS | NEKTAR THERAPEUTICS | 2016-10-06 | — | — | US | disclosed |
| US-9433684-B2 | Conjugates of small-interfering nucleic acids | NEKTAR THERAPEUTICS (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2016-06-23 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-20150038422-A1 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE | NEKTAR THERAPEUTICS | 2015-02-05 | — | — | US | disclosed |
| US-20140328791-A1 | Conjugates of an IL-2 Moiety and a Polymer | NEKTAR THERAPEUTICS | 2014-11-06 | — | — | US | disclosed |
| US-8586711-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS (US) | 2013-11-19 | — | — | US | disclosed |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038422-A1 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE | F8, F13B, F13A1 | SIRT2 4418/4885SIRT1 4430/4885HDAC4 4347/4885 |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | SIRT2 4529/4885SIRT1 4665/4885HDAC4 2498/4885 |
| US-20140328791-A1 | Conjugates of an IL-2 Moiety and a Polymer | IL2, IL2RA, ILF2 | SIRT2 507/4885SIRT1 3205/4885HDAC4 3879/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SIRT2 4221/4885SIRT1 4441/4885HDAC4 3660/4885 |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SIRT2 4162/4885SIRT1 3966/4885HDAC4 3492/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | SIRT2 4080/4885SIRT1 3908/4885HDAC4 3512/4885 |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | SIRT2 3408/4885SIRT1 3118/4885HDAC4 4046/4885 |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SIRT2 4221/4885SIRT1 4441/4885HDAC4 3660/4885 |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SIRT2 4157/4885SIRT1 4382/4885HDAC4 3625/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | SIRT2 4490/4885SIRT1 4397/4885HDAC4 3523/4885 |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SIRT2 4162/4885SIRT1 3966/4885HDAC4 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.